Compare Kyndryl Holdings Inc (KD) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Pfizer Inc — how do they compare? Kyndryl Holdings Inc trades at $11.75 (market cap $2.59B), while Pfizer Inc trades at $28.28 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 61.2× Kyndryl Holdings Inc's market cap, and Pfizer Inc pays a 6.18% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kyndryl Holdings Inc for 36 Days and Pfizer Inc for 158 Days on average.
| KD | PFE | |
|---|---|---|
Market Cap | $2.59B | $158.56B |
Volume | 5,354,348 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $29.76 | $29.02 |
52-Week Low | $10.59 | $23.67 |
Typical Hold Time | 36 Days | 158 Days |
Enterprise Value | $5.41B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl Holdings (KD) trades at $11.88, up 3.76% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported Q2 2026 EPS beat but missed Q4 2025 and Q1 2026 expectations. Fundamentals show improving profitability with 2025 net income of $252M (1.67% margin) and strong cash flow generation of $236M. Recent news highlights AI-focused initiatives including new innovation labs and strategic acquisitions.
Outlook remains cautious with analyst consensus at Hold (71.42%) and $14.67 price target offering 23% upside. Key risks include inconsistent earnings performance, competitive pressures in IT services, and high debt levels at 30.67% debt-to-asset ratio. The stock presents potential for recovery if AI investments translate to sustained revenue growth and margin expansion.
Pfizer (PFE) trades at $27.82, down 0.64% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company reported revenue of $62.58B in 2025 with a net income margin of 6.8%, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, positioning for a catalyst-rich 2026.
The stock presents a value opportunity with a forward P/E of 36.61 and consensus price target of $29.17, but faces risks from patent cliffs and volatile cash flows. Analyst sentiment is mixed with 40% buy ratings, while institutional outlook remains cautious amid earnings pressure and competitive threats in the pharma sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
